Merck and Roche Expand Agreement in Fight Against Chronic Hepatitis C

Merck MRK announced today that it has signed a new non-exclusive agreement with Roche, through the companies' respective subsidiaries, for the global promotion, upon appropriate marketing approvals, of VICTRELIS as part of a triple combination therapy regimen with peginterferon alfa and ribavirin.